Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
22.80
-0.55 (-2.36%)
At close: Jul 13, 2026, 4:00 PM EDT
22.72
-0.08 (-0.35%)
After-hours: Jul 13, 2026, 7:48 PM EDT
Immunome Market Cap
Immunome has a market cap or net worth of $2.58 billion as of July 13, 2026. Its market cap has increased by 237.60% in one year.
Market Cap
2.58B
Enterprise Value
2.00B
1-Year Change
237.60%
Ranking
Category
Stock Price
$22.80
Market Cap Chart
Since the IPO on October 2, 2020, Immunome's market cap has increased from $111.39M to $2.58B, an increase of 2,218.06%. That is a compound annual growth rate of 72.25%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 13, 2026 | 2.58B | 8.95% |
| Dec 31, 2025 | 2.37B | 257.53% |
| Dec 31, 2024 | 662.87M | 44.98% |
| Dec 29, 2023 | 457.21M | 1,605.70% |
| Dec 30, 2022 | 26.80M | -82.91% |
| Dec 31, 2021 | 156.82M | 53.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 2, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| MBX Biosciences | 2.91B |
| Kailera Therapeutics | 2.68B |
| Kodiak Sciences | 2.58B |
| Trevi Therapeutics | 2.53B |
| SELLAS Life Sciences Group | 2.51B |
| Mineralys Therapeutics | 2.50B |
| Tarsus Pharmaceuticals | 2.50B |
| Agios Pharmaceuticals | 2.45B |